Genetic Technologies Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GENE research report →
Price Chart
About the company
Genetic Technologies Limited (GTG. AX), an Australian molecular diagnostics company founded in Fitzroy in 1987, delivers predictive genetic testing and risk assessment tools. These solutions empower medical professionals in the United States, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific to proactively manage patient health.
- CEO
- Kevin Camilleri
- IPO
- 2005
- Employees
- 55
- HQ
- Fitzroy, VIC, AU
AI snapshot
Six angles, distilled from the data.
The stock is in a long downtrend and remains below its 200-day average, with the 50-day average flat at the current close. Price is sitting near the lower end of its 52-week range, which keeps the chart in a repair phase rather than a confirmed reversal.
Street coverage is thin and tilted negative: the published consensus is Sell, with no recent rating changes and no active buy/hold stack behind it. The lone target of 12.5 sits far above the current share price, but the lack of supporting revisions limits its weight.
Earnings history has been weak, with a 0/3 beat rate and no clear positive surprise trend. Revenue estimates point higher to 18.2 million for 2026 from 11.7 million for 2025, so shareholders should watch whether top-line traction can narrow losses.
No notable discretionary insider buying or selling. The recent filings are dominated by award and exempt transactions, which look like compensation-related grants and vesting rather than conviction trades.
Profitability remains under pressure, with a net margin of -124.2% and operating margin of -113.1%. Revenue fell 10.6% year over year, but gross margin still held at 61.1%, and the balance sheet shows modest net cash of 145,419.
GENE operates in diagnostics and research, where scale and recurring test adoption matter more than headline growth. Versus the sector, the setup is weaker on profitability and cash generation, while the valuation remains distressed rather than premium.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $111.24M
- P/E
- -0.43
- PEG
- -0.00
- P/S
- 0.74
- P/B
- 2.95
- EV/EBITDA
- -0.48
- Div Yield
- 0.00%
- Gross Margin
- 50.94%
- Op Margin
- -159.30%
- Net Margin
- -156.78%
- ROE
- -184.98%
- ROIC
- -429.43%
Latest fiscal year · YoY change
- Revenue
- $7.66M-25.9%
- Gross Profit
- $3.90M-35.1%
- Op Income
- $-12,210,212
- Net Income
- $-12,017,219-2.3%
- EPS
- $-2.73+24.3%
- OCF Growth
- +0.5%
- FCF Growth
- +0.3%
- 52W High
- $3.59
- 52W Low
- $0.67
- 50D MA
- $0.77
- 200D MA
- $1.07
- Beta
- 0.48
- RSI (14)
- 47
- Avg Volume
- 0
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Genetic Technologies said it is shifting from R&D into commercialization, with management targeting a pathway to profitability by mid-FY2025 and highlighting stronger U.S. commercial traction.· August 8, 2023
- FY2023 cash receipts were A$8.8 million, up 29% year over year, with gross margin of A$4.2 million (47%) and cash at bank of A$7.9 million.
- Q4 delivered A$2.1 million in cash receipts, and geneType commercial samples grew 250% quarter on quarter off a modest base.
- Management outlined a pathway to profitability driven by geneType growth, the hereditary breast and ovarian cancer test, and expansion of payer/distributor relationships in the U.S.
- The company said it now has 9 tests commercially available in the U.S. and 20 medical practices routinely sending tests, with more than 100 medical practices onboarded globally across the portfolio.
- ESG, cybersecurity, and operating discipline were presented as active workstreams, not side projects, with a baseline ESG report completed and security controls being upgraded.
For the year ended June 30, 2023, Genetic Technologies reported cash receipts of A$8.8 million, up 29% year over year, gross margin of A$4.2 million, or 47%, and cash at bank of A$7.9 million. In the quarter, cash receipts were A$2.1 million, and geneType commercial samples increased 250% versus the prior quarter. Management said the company believes a pathway to profitability could be achieved by the middle of financial year 2025. No formal next-quarter revenue or EPS guidance was provided; instead, the company pointed to upcoming milestones including the launch of the UNITY prenatal test, a hereditary breast and ovarian cancer test, and a pilot with a payer or medical institution.
Simon Morriss emphasized that the business is moving from a long R&D phase into commercialization and then toward profitability, with revenue growth as the central priority. He repeatedly framed the strategy around three brands — geneType, EasyDNA, and Affinity DNA — plus a multi-channel model spanning B2B payers/distributors, consumer-initiated testing, and direct-to-consumer. His tone was optimistic and milestone-driven, highlighting U.S. commercial progress, upcoming clinical validation work, and new product launches as the key next steps.
Tony Di Pietro focused on integration and control after the acquisitions, saying the two businesses bought in the last two years broadened exposure to direct-to-consumer markets and European operations. He said systems and reporting lines have now been embedded, with efficiency gains now the focus, and noted the challenge of managing a globally distributed business from Melbourne across multiple time zones. On risk management, he said cybersecurity has long been a priority because of patient data, and that the new businesses have moved to Office 365 while Melbourne is undergoing a similar upgrade.
Analysts asked about the main growth drivers, and management said the core levers are sales from the existing EasyDNA and Affinity businesses, growth in geneType, and especially securing a U.S. payer or distributor relationship. On ESG, management rejected the idea that it is box ticking, saying investors care about it and the company has completed a baseline report and is now setting milestones. On U.S. payer talks, Carl Stubbings said the team is close to finalizing the foundation for reimbursement discussions and that a pilot should help move other payer conversations forward.
The positive case from the call is that the company showed clear revenue momentum, with 29% annual growth in cash receipts and a 250% increase in geneType commercial samples quarter on quarter. Management also pointed to multiple near-term catalysts: new U.S. hires, a planned payer pilot, the hereditary breast and ovarian cancer launch, and additional clinical validation publications.
The main risk is that the profitability plan depends on execution across several moving pieces, including payer adoption, distribution deals, and timely product launches. Management also acknowledged that some growth is coming from a modest base, that direct-to-consumer expansion has had technical and jurisdictional challenges, and that reimbursement in the U.S. is a long process with no guaranteed outcome.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 95.3%
- Shares Outstanding
- 4.85M
- Float Shares
- 4.62M
of shares held by institutions
10 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Virtu Kcg Holdings LLC | 85.96K | ▲ 85.96K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 24, 04 | PATOU GARY | other | 2,500 |
| Aug 25, 04 | PATOU GARY | other | 5,500 |
| Jul 1, 04 | HENNESSEY ROBERT J | other | 1,500 |
| Jun 29, 04 | KIRBY PAMELA J | other | 9,047 |
| Jun 29, 04 | KIRBY PAMELA J | other | 25,000 |
| Jun 29, 04 | KIRBY PAMELA J | other | 0 |
| May 5, 04 | STONE DAVID K | other | 184 |
| May 5, 04 | RIEDEL NORBERT G | other | 184 |
| Apr 13, 04 | HENNESSEY ROBERT J | other | 10,947 |
| Apr 13, 04 | HENNESSEY ROBERT J | other | 25,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our GENE coverage
Recent articles, reports, and earnings notes.
No research on GENE yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate GENE report →The Silk Road Gets a Spidey Genetic Upgrade
globenewswire.com · Nov 19
Scribe Therapeutics Presents New Data Advancing the Potential of Ultra-Long-Acting Genetic Medicines for Cardiovascular Disease at AHA Scientific Sessions 2026
globenewswire.com · Nov 18
Lexeo Therapeutics Cuts Arrhythmia Burden by 80% in Genetic Heart Disease Study
benzinga.com · Nov 16
Madrigal Announces Publication in the Journal of Hepatology Demonstrating Consistent Rezdiffra Efficacy Across Common MASH Genetic Risk Variants
globenewswire.com · Oct 6
Genetic discovery yields clues toward reversal of Alzheimer's brain damage
reuters.com · Sep 25
Armata Pharmaceuticals to Present Data at ISSSI 2026 Showing Defined Genetic Diversity in AP-SA02 May Enhance Killing of Certain Staphylococcus aureus Clinical Isolates
prnewswire.com · Sep 21
Kala Bio and Virotek Finalize Definitive Agreement Establishing Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program
globenewswire.com · Sep 3
Kala Bio and Virotek Announce Letter of Intent to Establish an Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program
globenewswire.com · Sep 1
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 21, 2026 · Live quote · Not investment advice